Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/27408
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorCarraro, M.-
dc.contributor.authorComi, G.-
dc.contributor.authorIzquierdo, G.-
dc.contributor.authorKim, H. J.-
dc.contributor.authorSharrack, B.-
dc.contributor.authorTornatore, C.-
dc.contributor.authorDaizadeh, N.-
dc.contributor.authorMelanson, M.-
dc.contributor.authorJacobs, Alessia-
dc.contributor.authorWiendl, H.-
dc.date.accessioned2018-11-15T13:43:58Z-
dc.date.available2018-11-15T13:43:58Z-
dc.date.issued2018-
dc.identifier.citationEUROPEAN JOURNAL OF NEUROLOGY, 25(S2), p. 535-535 (Art N° EPR3102)-
dc.identifier.issn1351-5101-
dc.identifier.urihttp://hdl.handle.net/1942/27408-
dc.description.sponsorshipSanofi; Bayer HealthCare Pharmaceuticals-
dc.language.isoen-
dc.publisherWILEY-
dc.titleLack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 16-19, 2018-
local.bibliographicCitation.conferencename4th Congress of the European-Academy-of-Neurology (EAN)-
local.bibliographicCitation.conferenceplaceLisbon, PORTUGAL-
dc.identifier.epage535-
dc.identifier.issueS2-
dc.identifier.spage535-
dc.identifier.volume25-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[van Wijmeersch, B.] Hasselt Univ, BIOMED, Rehabil & MS Ctr Overpelt, Hasselt, Belgium. [Carraro, M.] Novant Hlth, Charlotte, NC USA. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Izquierdo, G.] Virgen Macarena Univ Hosp, Seville, Spain. [Kim, H. J.] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea. [Sharrack, B.] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England. [Tornatore, C.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA. [Daizadeh, N.; Melanson, M.; Jacobs, A.] Sanofi, Cambridge, MA USA. [Wiendl, H.] Univ Munster, Munster, Germany.-
local.publisher.placeHOBOKEN-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrEPR3102-
dc.identifier.isi000435272002422-
item.fulltextWith Fulltext-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorCarraro, M.-
item.contributorComi, G.-
item.contributorIzquierdo, G.-
item.contributorKim, H. J.-
item.contributorSharrack, B.-
item.contributorTornatore, C.-
item.contributorDaizadeh, N.-
item.contributorMelanson, M.-
item.contributorJacobs, Alessia-
item.contributorWiendl, H.-
item.fullcitationVAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia & Wiendl, H. (2018) Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension. In: EUROPEAN JOURNAL OF NEUROLOGY, 25(S2), p. 535-535 (Art N° EPR3102).-
item.accessRightsOpen Access-
crisitem.journal.issn1351-5101-
crisitem.journal.eissn1468-1331-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
p 535 2018-European_Journal_of_Neurology.pdfPublished version147.66 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.